KCCQ-CSS (Kansas City Cardiomyopathy Questionnaire, Clinical Summary Score)
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is KCCQ-CSS (Kansas City Cardiomyopathy Questionnaire, Clinical Summary Score)?
The clinical summary score from the Kansas City Cardiomyopathy Questionnaire: a validated, patient-reported measure of heart-failure symptoms and physical limitation.
It is scored 0–100, higher is better, and five points is the threshold for clinically meaningful. In STEP-HFpEF the score rose 16.6 points on semaglutide against 8.7 on placebo, a 7.8-point difference, and it was one of the trial's two primary endpoints.
Top GLP-1 cardiovascular studies →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where KCCQ-CSS (Kansas City Cardiomyopathy Questionnaire, Clinical Summary Score) comes up on this site
Connected terms
Other terms under Major trials
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers